CA2896673A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii - Google Patents

Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii Download PDF

Info

Publication number
CA2896673A1
CA2896673A1 CA2896673A CA2896673A CA2896673A1 CA 2896673 A1 CA2896673 A1 CA 2896673A1 CA 2896673 A CA2896673 A CA 2896673A CA 2896673 A CA2896673 A CA 2896673A CA 2896673 A1 CA2896673 A1 CA 2896673A1
Authority
CA
Canada
Prior art keywords
mal
ppi
iii
dendrimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2896673A
Other languages
English (en)
French (fr)
Inventor
Ida FRANIAK-PIETRYGA
Maria BRYSZEWSKA
Dietmar Appelhans
Barbara KLAJNERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Łódź
Original Assignee
University of Łódź
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Łódź filed Critical University of Łódź
Publication of CA2896673A1 publication Critical patent/CA2896673A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2896673A 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii Abandoned CA2896673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.401934 2012-12-06
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PCT/PL2013/000154 WO2014088434A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii

Publications (1)

Publication Number Publication Date
CA2896673A1 true CA2896673A1 (en) 2014-06-12

Family

ID=49955471

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896673A Abandoned CA2896673A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii

Country Status (9)

Country Link
US (1) US20150320692A1 (cg-RX-API-DMAC10.html)
EP (1) EP2928478A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501260A (cg-RX-API-DMAC10.html)
KR (1) KR20150099539A (cg-RX-API-DMAC10.html)
AU (1) AU2013356792A1 (cg-RX-API-DMAC10.html)
CA (1) CA2896673A1 (cg-RX-API-DMAC10.html)
IL (1) IL239143A0 (cg-RX-API-DMAC10.html)
PL (1) PL234887B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088434A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) * 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
JP2016501260A (ja) 2016-01-18
PL234887B1 (pl) 2020-04-30
EP2928478A1 (en) 2015-10-14
US20150320692A1 (en) 2015-11-12
KR20150099539A (ko) 2015-08-31
IL239143A0 (en) 2015-07-30
AU2013356792A1 (en) 2015-07-23
PL401934A1 (pl) 2014-06-09
WO2014088434A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
Li et al. Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C/Apaf-1/Caspase-9/Caspase-3 signaling pathway in vitro
Hsin et al. The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells
Shang et al. Platelet-membrane-camouflaged black phosphorus quantum dots enhance anticancer effect mediated by apoptosis and autophagy
Zhu et al. Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism
Liu et al. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways
Zanotto-Filho et al. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma
Manna et al. RETRACTED ARTICLE: contribution of nano-copper particles to in vivo liver dysfunction and cellular damage: role of IκBα/NF-κB, MAPKs and mitochondrial signal
Könczöl et al. Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: Role of ROS, JNK, and NF-κB
Yusuf et al. Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis
Wu et al. Vacuolization in cytoplasm and cell membrane permeability enhancement triggered by micrometer-sized graphene oxide
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
Gui et al. Nanoscale coordination polymer Fe-DMY downregulating Poldip2-Nox4-H2O2 pathway and alleviating diabetic retinopathy
Zhang et al. α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer
Nie et al. Selenium speciation-dependent cancer radiosensitization by induction of G2/M cell cycle arrest and apoptosis
Knotigova et al. Application of advanced microscopic methods to study the interaction of carboxylated fluorescent nanodiamonds with membrane structures in THP-1 cells: activation of inflammasome NLRP3 as the result of lysosome destabilization
Ünsal et al. The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro
Makkar et al. Molecular insight to size and dose-dependent cellular toxicity exhibited by a green synthesized bioceramic nanohybrid with macrophages for dental applications
Su et al. Roles of PTEN gene methylation in Se-CQDs induced mitochondrial apoptosis of osteosarcoma cells
Gorojod et al. Nanohydroxyapatite exerts cytotoxic effects and prevents cellular proliferation and migration in glioma cells
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
EP2788007B1 (en) Use of silver(i) complexes as anticancer agents
Zhang et al. Sulforaphane Functionalized Chitosan Nanoparticles Serve as an Effective Nanocomplex System for the Treatment of Human Cervical Cancer: X. Zhang et al.
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
Jiang et al. Iterative‐Designed Multifunctional Carbon Dots Nanodrug for Celastrol Loading, Targeting Delivery, and Combination Therapy of Kidney Stones

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191203